首页 > 最新文献

Virology: Research and Treatment最新文献

英文 中文
Animal Models Utilized in HTLV-1 Research. HTLV-1研究中使用的动物模型
Q1 Medicine Pub Date : 2013-11-18 eCollection Date: 2013-01-01 DOI: 10.4137/VRT.S12140
Amanda R Panfil, Jacob J Al-Saleem, Patrick L Green

Since the isolation and discovery of human T-cell leukemia virus type 1 (HTLV-1) over 30 years ago, researchers have utilized animal models to study HTLV-1 transmission, viral persistence, virus-elicited immune responses, and HTLV-1-associated disease development (ATL, HAM/TSP). Non-human primates, rabbits, rats, and mice have all been used to help understand HTLV-1 biology and disease progression. Non-human primates offer a model system that is phylogenetically similar to humans for examining viral persistence. Viral transmission, persistence, and immune responses have been widely studied using New Zealand White rabbits. The advent of molecular clones of HTLV-1 has offered the opportunity to assess the importance of various viral genes in rabbits, non-human primates, and mice. Additionally, over-expression of viral genes using transgenic mice has helped uncover the importance of Tax and Hbz in the induction of lymphoma and other lymphocyte-mediated diseases. HTLV-1 inoculation of certain strains of rats results in histopathological features and clinical symptoms similar to that of humans with HAM/TSP. Transplantation of certain types of ATL cell lines in immunocompromised mice results in lymphoma. Recently, "humanized" mice have been used to model ATL development for the first time. Not all HTLV-1 animal models develop disease and those that do vary in consistency depending on the type of monkey, strain of rat, or even type of ATL cell line used. However, the progress made using animal models cannot be understated as it has led to insights into the mechanisms regulating viral replication, viral persistence, disease development, and, most importantly, model systems to test disease treatments.

自30多年前分离和发现人类t细胞白血病病毒1型(HTLV-1)以来,研究人员利用动物模型研究HTLV-1传播、病毒持久性、病毒引发的免疫反应以及HTLV-1相关疾病的发展(ATL, HAM/TSP)。非人类灵长类动物、兔子、大鼠和小鼠都被用来帮助了解HTLV-1生物学和疾病进展。非人类灵长类动物提供了一个与人类在系统发育上相似的模型系统,用于检测病毒的持久性。病毒的传播、持久性和免疫反应在新西兰白兔身上得到了广泛的研究。HTLV-1分子克隆的出现为评估兔、非人类灵长类动物和小鼠中各种病毒基因的重要性提供了机会。此外,利用转基因小鼠过度表达病毒基因有助于揭示Tax和Hbz在诱导淋巴瘤和其他淋巴细胞介导的疾病中的重要性。HTLV-1接种某些大鼠毒株可导致与HAM/TSP患者相似的组织病理学特征和临床症状。在免疫功能低下的小鼠中移植某些类型的ATL细胞系可导致淋巴瘤。最近,“人源化”小鼠首次被用于模拟ATL的发育。并不是所有的HTLV-1动物模型都会发病,根据猴子的类型、大鼠的品系,甚至使用的ATL细胞系的类型,这些模型的一致性有所不同。然而,使用动物模型取得的进展不能被低估,因为它已经导致对调节病毒复制,病毒持久性,疾病发展的机制的见解,最重要的是,模型系统来测试疾病治疗。
{"title":"Animal Models Utilized in HTLV-1 Research.","authors":"Amanda R Panfil,&nbsp;Jacob J Al-Saleem,&nbsp;Patrick L Green","doi":"10.4137/VRT.S12140","DOIUrl":"https://doi.org/10.4137/VRT.S12140","url":null,"abstract":"<p><p>Since the isolation and discovery of human T-cell leukemia virus type 1 (HTLV-1) over 30 years ago, researchers have utilized animal models to study HTLV-1 transmission, viral persistence, virus-elicited immune responses, and HTLV-1-associated disease development (ATL, HAM/TSP). Non-human primates, rabbits, rats, and mice have all been used to help understand HTLV-1 biology and disease progression. Non-human primates offer a model system that is phylogenetically similar to humans for examining viral persistence. Viral transmission, persistence, and immune responses have been widely studied using New Zealand White rabbits. The advent of molecular clones of HTLV-1 has offered the opportunity to assess the importance of various viral genes in rabbits, non-human primates, and mice. Additionally, over-expression of viral genes using transgenic mice has helped uncover the importance of Tax and Hbz in the induction of lymphoma and other lymphocyte-mediated diseases. HTLV-1 inoculation of certain strains of rats results in histopathological features and clinical symptoms similar to that of humans with HAM/TSP. Transplantation of certain types of ATL cell lines in immunocompromised mice results in lymphoma. Recently, \"humanized\" mice have been used to model ATL development for the first time. Not all HTLV-1 animal models develop disease and those that do vary in consistency depending on the type of monkey, strain of rat, or even type of ATL cell line used. However, the progress made using animal models cannot be understated as it has led to insights into the mechanisms regulating viral replication, viral persistence, disease development, and, most importantly, model systems to test disease treatments. </p>","PeriodicalId":39174,"journal":{"name":"Virology: Research and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/VRT.S12140","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32911523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
T Cell Transcription Factors and Their Impact on HIV Expression. T细胞转录因子及其对HIV表达的影响
Q1 Medicine Pub Date : 2013-09-24 DOI: 10.4137/VRT.S12147
Katarzyna Kaczmarek, Ayana Morales, Andrew J Henderson

By targeting CD4+ effector T cells, HIV has a dramatic impact on the depletion, expansion and function of the different polarized T cell subsets. The maturation of T cell lineages is in part driven by intrinsic transcription factors that potentially influence how efficiently HIV replicates. In this review, we explore whether transcription factors that are required for polarizing T cells influence HIV replication. In particular, we examine provirus transcription as well as the establishment and maintenance of HIV latency. Furthermore, it is suggested these factors may provide novel cell-specific therapeutic strategies for targeting the HIV latent reservoir.

HIV通过靶向CD4+效应T细胞,对不同极化T细胞亚群的耗竭、扩增和功能产生巨大影响。T细胞谱系的成熟部分是由潜在影响HIV复制效率的内在转录因子驱动的。在这篇综述中,我们探讨了T细胞极化所需的转录因子是否影响HIV复制。特别是,我们研究了原病毒转录以及HIV潜伏期的建立和维持。此外,这些因素可能为靶向HIV潜伏库提供新的细胞特异性治疗策略。
{"title":"T Cell Transcription Factors and Their Impact on HIV Expression.","authors":"Katarzyna Kaczmarek,&nbsp;Ayana Morales,&nbsp;Andrew J Henderson","doi":"10.4137/VRT.S12147","DOIUrl":"https://doi.org/10.4137/VRT.S12147","url":null,"abstract":"<p><p>By targeting CD4<sup>+</sup> effector T cells, HIV has a dramatic impact on the depletion, expansion and function of the different polarized T cell subsets. The maturation of T cell lineages is in part driven by intrinsic transcription factors that potentially influence how efficiently HIV replicates. In this review, we explore whether transcription factors that are required for polarizing T cells influence HIV replication. In particular, we examine provirus transcription as well as the establishment and maintenance of HIV latency. Furthermore, it is suggested these factors may provide novel cell-specific therapeutic strategies for targeting the HIV latent reservoir.</p>","PeriodicalId":39174,"journal":{"name":"Virology: Research and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/VRT.S12147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32038546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
High Rate of Non-detectable HIV-1 RNA Among Antiretroviral Drug Naive HIV Positive Individuals in Nigeria. 尼日利亚抗逆转录病毒药物初始HIV阳性个体中检测不到HIV-1 RNA的高比率
Q1 Medicine Pub Date : 2013-08-28 eCollection Date: 2013-01-01 DOI: 10.4137/VRT.S12677
Georgina N Odaibo, Isaac F Adewole, David O Olaleye

Plasma HIV-1 RNA concentration, or viral load, is an indication of the magnitude of virus replication and largely correlates with disease progression in an infected person. It is a very useful guide for initiation of therapy and monitoring of response to antiretroviral drugs. Although the majority of patients who are not on antiretroviral therapy (ART) have a high viral load, a small proportion of ART naive patients are known to maintain low levels or even undetectable viral load levels. In this study, we determined the rate of undetectable HIV-1 RNA among ART naive HIV positive patients who presented for treatment at the University College Hospital (UCH), Ibadan, Nigeria from 2005 to 2011. Baseline viral load and CD4 lymphocyte cell counts of 14,662 HIV positive drug naive individuals were determined using the Roche Amplicor version 1.5 and Partec easy count kit, respectively. The detection limits of the viral load assay are 400 copies/mL and 750,000 copies/mL for lower and upper levels, respectively. A total of 1,399 of the 14,662 (9.5%) HIV-1 positive drug naive individuals had undetectable viral load during the study period. In addition, the rate of non-detectable viral load increased over the years. The mean CD4 counts among HIV-1 infected individuals with detectable viral load (266 cells/μL; range = 1 to 2,699 cells/μL) was lower than in patients with undetectable viral load (557 cells/μL; range = 1 to 3,102 cells/μL). About 10% of HIV-1 infected persons in our study population had undetectable viral load using the Roche Amplicor version 1.5.

血浆HIV-1 RNA浓度或病毒载量是病毒复制程度的一个指标,在很大程度上与感染者的疾病进展相关。这是一个非常有用的指南,开始治疗和监测对抗逆转录病毒药物的反应。虽然大多数未接受抗逆转录病毒治疗(ART)的患者具有高病毒载量,但已知一小部分初次接受ART治疗的患者维持低水平甚至无法检测到病毒载量水平。在这项研究中,我们确定了2005年至2011年在尼日利亚伊巴丹大学学院医院(UCH)接受治疗的抗逆转录病毒治疗的初发HIV阳性患者中检测不到HIV-1 RNA的比率。使用Roche Amplicor version 1.5和Partec easy计数试剂盒分别测定14662例HIV阳性药物初治个体的基线病毒载量和CD4淋巴细胞计数。病毒载量检测下限为400 copies/mL,上限为750,000 copies/mL。在研究期间,14662例HIV-1阳性药物初始个体中有1399例(9.5%)的病毒载量检测不到。此外,多年来,无法检测到病毒载量的比率有所增加。病毒载量检测到的HIV-1感染者的平均CD4计数(266个细胞/μL;范围= 1 ~ 2,699个细胞/μL)低于未检测到病毒载量的患者(557个细胞/μL;范围= 1 ~ 3102 cells/μL)。在我们的研究人群中,约有10%的HIV-1感染者使用罗氏扩增1.5版检测不到病毒载量。
{"title":"High Rate of Non-detectable HIV-1 RNA Among Antiretroviral Drug Naive HIV Positive Individuals in Nigeria.","authors":"Georgina N Odaibo,&nbsp;Isaac F Adewole,&nbsp;David O Olaleye","doi":"10.4137/VRT.S12677","DOIUrl":"https://doi.org/10.4137/VRT.S12677","url":null,"abstract":"<p><p>Plasma HIV-1 RNA concentration, or viral load, is an indication of the magnitude of virus replication and largely correlates with disease progression in an infected person. It is a very useful guide for initiation of therapy and monitoring of response to antiretroviral drugs. Although the majority of patients who are not on antiretroviral therapy (ART) have a high viral load, a small proportion of ART naive patients are known to maintain low levels or even undetectable viral load levels. In this study, we determined the rate of undetectable HIV-1 RNA among ART naive HIV positive patients who presented for treatment at the University College Hospital (UCH), Ibadan, Nigeria from 2005 to 2011. Baseline viral load and CD4 lymphocyte cell counts of 14,662 HIV positive drug naive individuals were determined using the Roche Amplicor version 1.5 and Partec easy count kit, respectively. The detection limits of the viral load assay are 400 copies/mL and 750,000 copies/mL for lower and upper levels, respectively. A total of 1,399 of the 14,662 (9.5%) HIV-1 positive drug naive individuals had undetectable viral load during the study period. In addition, the rate of non-detectable viral load increased over the years. The mean CD4 counts among HIV-1 infected individuals with detectable viral load (266 cells/μL; range = 1 to 2,699 cells/μL) was lower than in patients with undetectable viral load (557 cells/μL; range = 1 to 3,102 cells/μL). About 10% of HIV-1 infected persons in our study population had undetectable viral load using the Roche Amplicor version 1.5. </p>","PeriodicalId":39174,"journal":{"name":"Virology: Research and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/VRT.S12677","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32913152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Antigenic Variation in H5N1 clade 2.1 Viruses in Indonesia From 2005 to 2011. 2005 - 2011年印度尼西亚H5N1分支2.1病毒的抗原变异
Q1 Medicine Pub Date : 2013-08-19 eCollection Date: 2013-01-01 DOI: 10.4137/VRT.S11754
Vivi Setiawaty, Eka Pratiwi, Hana A Pawestri, Fera Ibrahim, Amin Soebandrio

Influenza A (H5N1) virus, has spread to several countries in the world and has a high mortality rate. Meanwhile, the virus has evolved into several clades. The human influenza A (H5N1) virus circulating in Indonesia is a member of clade 2.1, which is different in antigenicity from other clades of influenza A (H5N1). An analysis of the antigenic variation in the H5 hemagglutinin gene (HA) of the influenza A (H5N1) virus strains circulating in Indonesia has been undertaken. Several position of amino acid mutations, including mutations at positions 35, 53, 141, 145, 163, 174, 183, 184, 189, and 231, have been identified. The mutation Val-174-Iso appears to play an important role in immunogenicity and cross-reactivity with rabbit antisera. This study shows that the evolution of the H5HA antigenic variation of the influenza A (H5N1) virus circulating in Indonesia from 2005 to 2011 may affect the immunogenicity of the virus.

甲型流感(H5N1)病毒已传播到世界上几个国家,死亡率很高。与此同时,病毒已经进化成几个分支。在印度尼西亚流行的人甲型H5N1流感病毒是2.1进化支的成员,其抗原性与其他甲型H5N1流感进化支不同。对在印度尼西亚流行的甲型流感(H5N1)病毒株H5血凝素基因(HA)的抗原变异进行了分析。已经确定了氨基酸突变的几个位置,包括位置35、53、141、145、163、174、183、184、189和231的突变。突变Val-174-Iso似乎在免疫原性和与兔抗血清的交叉反应性中起重要作用。本研究表明,2005 - 2011年在印度尼西亚流行的甲型H5N1流感病毒H5HA抗原变异的演变可能影响该病毒的免疫原性。
{"title":"Antigenic Variation in H5N1 clade 2.1 Viruses in Indonesia From 2005 to 2011.","authors":"Vivi Setiawaty,&nbsp;Eka Pratiwi,&nbsp;Hana A Pawestri,&nbsp;Fera Ibrahim,&nbsp;Amin Soebandrio","doi":"10.4137/VRT.S11754","DOIUrl":"https://doi.org/10.4137/VRT.S11754","url":null,"abstract":"<p><p>Influenza A (H5N1) virus, has spread to several countries in the world and has a high mortality rate. Meanwhile, the virus has evolved into several clades. The human influenza A (H5N1) virus circulating in Indonesia is a member of clade 2.1, which is different in antigenicity from other clades of influenza A (H5N1). An analysis of the antigenic variation in the H5 hemagglutinin gene (HA) of the influenza A (H5N1) virus strains circulating in Indonesia has been undertaken. Several position of amino acid mutations, including mutations at positions 35, 53, 141, 145, 163, 174, 183, 184, 189, and 231, have been identified. The mutation Val-174-Iso appears to play an important role in immunogenicity and cross-reactivity with rabbit antisera. This study shows that the evolution of the H5HA antigenic variation of the influenza A (H5N1) virus circulating in Indonesia from 2005 to 2011 may affect the immunogenicity of the virus. </p>","PeriodicalId":39174,"journal":{"name":"Virology: Research and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/VRT.S11754","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32913151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle? 树突状细胞在HIV-1和HCV感染中的作用:它们能帮助赢得战斗吗?
Q1 Medicine Pub Date : 2013-02-11 eCollection Date: 2013-01-01 DOI: 10.4137/VRT.S11046
Mohit Sehgal, Zafar K Khan, Andrew H Talal, Pooja Jain

Persistent infections with human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) are a major cause of morbidity and mortality worldwide. As sentinels of our immune system, dendritic cells (DCs) play a central role in initiating and regulating a potent antiviral immune response. Recent advances in our understanding of the role of DCs during HIV-1 and HCV infection have provided crucial insights into the mechanisms employed by these viruses to impair DC functions in order to evade an effective immune response against them. Modulation of the immunological synapse between DC and T-cell, as well as dysregulation of the crosstalk between DCs and natural killer (NK) cells, are emerging as two crucial mechanisms. This review focuses on understanding the interaction of HIV-1 and HCV with DCs not only to understand the immunopathogenesis of chronic HIV-1 and HCV infection, but also to explore the possibilities of DC-based immunotherapeutic approaches against them. Host genetic makeup is known to play major roles in infection outcome and rate of disease progression, as well as response to anti-viral therapy in both HIV-1 and HCV-infected individuals. Therefore, we highlight the genetic variations that can potentially affect DC functions, especially in the setting of chronic viral infection. Altogether, we address if DCs' potential as critical effectors of antiviral immune response could indeed be utilized to combat chronic infection with HIV-1 and HCV.

人类免疫缺陷病毒1型(HIV-1)和丙型肝炎病毒(HCV)的持续感染是世界范围内发病率和死亡率的主要原因。作为我们免疫系统的哨兵,树突状细胞(dc)在启动和调节有效的抗病毒免疫反应中起着核心作用。最近我们对DC在HIV-1和HCV感染中的作用的理解取得了进展,这为这些病毒破坏DC功能以逃避对它们的有效免疫应答的机制提供了重要的见解。DC和t细胞之间的免疫突触的调节,以及DC和自然杀伤细胞(NK)之间的串扰的失调,是两个重要的机制。本文综述了HIV-1和HCV与dc的相互作用,不仅是为了了解慢性HIV-1和HCV感染的免疫发病机制,也是为了探索基于dc的免疫治疗方法的可能性。已知宿主基因组成在HIV-1和hcv感染个体的感染结果和疾病进展率以及抗病毒治疗反应中发挥重要作用。因此,我们强调了可能影响DC功能的遗传变异,特别是在慢性病毒感染的情况下。总之,我们讨论了dc作为抗病毒免疫反应关键效应物的潜力是否确实可以用于对抗HIV-1和HCV的慢性感染。
{"title":"Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle?","authors":"Mohit Sehgal,&nbsp;Zafar K Khan,&nbsp;Andrew H Talal,&nbsp;Pooja Jain","doi":"10.4137/VRT.S11046","DOIUrl":"https://doi.org/10.4137/VRT.S11046","url":null,"abstract":"<p><p>Persistent infections with human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) are a major cause of morbidity and mortality worldwide. As sentinels of our immune system, dendritic cells (DCs) play a central role in initiating and regulating a potent antiviral immune response. Recent advances in our understanding of the role of DCs during HIV-1 and HCV infection have provided crucial insights into the mechanisms employed by these viruses to impair DC functions in order to evade an effective immune response against them. Modulation of the immunological synapse between DC and T-cell, as well as dysregulation of the crosstalk between DCs and natural killer (NK) cells, are emerging as two crucial mechanisms. This review focuses on understanding the interaction of HIV-1 and HCV with DCs not only to understand the immunopathogenesis of chronic HIV-1 and HCV infection, but also to explore the possibilities of DC-based immunotherapeutic approaches against them. Host genetic makeup is known to play major roles in infection outcome and rate of disease progression, as well as response to anti-viral therapy in both HIV-1 and HCV-infected individuals. Therefore, we highlight the genetic variations that can potentially affect DC functions, especially in the setting of chronic viral infection. Altogether, we address if DCs' potential as critical effectors of antiviral immune response could indeed be utilized to combat chronic infection with HIV-1 and HCV. </p>","PeriodicalId":39174,"journal":{"name":"Virology: Research and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/VRT.S11046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32911522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Intrabody-based Mapping of Latency-associated Nuclear Antigen from Kaposi's Sarcoma-associated Herpesvirus Show Conserved Epitopes for Viral Latency Inhibition 卡波西肉瘤相关疱疹病毒潜伏期相关核抗原的体内定位显示病毒潜伏期抑制的保守表位
Q1 Medicine Pub Date : 2010-01-01 DOI: 10.4137/VRT.S975
Sofia Corte-Real, Lídia Fonseca, C. Barbas, J. Gonçalves
Kaposi's sarcoma associated herpesvirus (KSHV or human herpesvirus 8 [HHV-8]) is a gammaherpesvirus highly associated with KS, primary effusion lymphoma (PEL), and multicentric Castleman's disease, an aggressive lymphoproliferative disorder. KSHV, like other gammaherpesvirus latently infects predominantly B-cells and endothelial cells. Infected cells retain the virus from one generation to the next existing as a multicopy circular episomal DNA in the nucleus, expressing a limited subset of viral genes. Of these latently expressed genes, LANA1, the latency associated nuclear antigen is highly expressed in all forms of KS-associated malignancies. Various studies so far show that LANA1 tethers the viral episomes to host chromosomes and binds to specific sites within and close to the TR elements contributing to the stable maintenance of the viral episomes in successive daughter cells. Anti-LANA1 intrabody strategies might represent a new therapeutic approach to treatment of KSHV infections, since LANA1 is regained for KSHV latency. In addition, the use of intrabodies can help drug development by mapping LANA1 inhibiting regions. We report development of several LANA1 specific single chain antibodies from immunized rabbits that can be expressed intracellularly, bind to LANA1 epitopes and can be used for functional KSHV studies on viral latency.
卡波西肉瘤相关疱疹病毒(KSHV或人类疱疹病毒8 [HHV-8])是一种伽玛疱疹病毒,与KS、原发性积液性淋巴瘤(PEL)和多中心Castleman病(一种侵袭性淋巴增生性疾病)高度相关。KSHV,像其他伽玛疱疹病毒一样,主要潜伏感染b细胞和内皮细胞。受感染的细胞将病毒作为细胞核内的多拷贝环状外体细胞DNA代代保留,表达有限的病毒基因子集。在这些潜伏表达的基因中,潜伏相关核抗原LANA1在所有形式的ks相关恶性肿瘤中高度表达。到目前为止,各种研究表明,LANA1将病毒片段连接到宿主染色体上,并结合到TR元件内部和附近的特定位点,有助于在连续的子细胞中稳定维持病毒片段。抗LANA1体内策略可能是治疗KSHV感染的一种新的治疗方法,因为LANA1会在KSHV潜伏期恢复。此外,使用体内可以通过绘制LANA1抑制区域来帮助药物开发。我们报道了几种LANA1特异性单链抗体的发展,这些抗体可以在细胞内表达,与LANA1表位结合,并可用于功能性KSHV病毒潜伏期的研究。
{"title":"Intrabody-based Mapping of Latency-associated Nuclear Antigen from Kaposi's Sarcoma-associated Herpesvirus Show Conserved Epitopes for Viral Latency Inhibition","authors":"Sofia Corte-Real, Lídia Fonseca, C. Barbas, J. Gonçalves","doi":"10.4137/VRT.S975","DOIUrl":"https://doi.org/10.4137/VRT.S975","url":null,"abstract":"Kaposi's sarcoma associated herpesvirus (KSHV or human herpesvirus 8 [HHV-8]) is a gammaherpesvirus highly associated with KS, primary effusion lymphoma (PEL), and multicentric Castleman's disease, an aggressive lymphoproliferative disorder. KSHV, like other gammaherpesvirus latently infects predominantly B-cells and endothelial cells. Infected cells retain the virus from one generation to the next existing as a multicopy circular episomal DNA in the nucleus, expressing a limited subset of viral genes. Of these latently expressed genes, LANA1, the latency associated nuclear antigen is highly expressed in all forms of KS-associated malignancies. Various studies so far show that LANA1 tethers the viral episomes to host chromosomes and binds to specific sites within and close to the TR elements contributing to the stable maintenance of the viral episomes in successive daughter cells. Anti-LANA1 intrabody strategies might represent a new therapeutic approach to treatment of KSHV infections, since LANA1 is regained for KSHV latency. In addition, the use of intrabodies can help drug development by mapping LANA1 inhibiting regions. We report development of several LANA1 specific single chain antibodies from immunized rabbits that can be expressed intracellularly, bind to LANA1 epitopes and can be used for functional KSHV studies on viral latency.","PeriodicalId":39174,"journal":{"name":"Virology: Research and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/VRT.S975","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70717315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV-1 Transmission, Replication Fitness and Disease Progression. HIV-1的传播、复制适应性和疾病进展。
Q1 Medicine Pub Date : 2008-07-14
Tasha Biesinger, Jason T Kimata

Upon transmission, human immunodeficiency virus type 1 (HIV-1) establishes infection of the lymphatic reservoir, leading to profound depletion of the memory CD4(+) T cell population, despite the induction of the adaptive immune response. The rapid evolution and association of viral variants having distinct characteristics with different stages of infection, the level of viral burden, and rate of disease progression suggest a role for viral variants in this process. Here, we review the literature on HIV-1 variants and disease and discuss the importance of viral fitness for transmission and disease.

在传播后,人类免疫缺陷病毒1型(HIV-1)建立淋巴库感染,导致记忆性CD4(+) T细胞群的严重耗竭,尽管诱导了适应性免疫反应。在感染的不同阶段、病毒负荷水平和疾病进展速度中具有不同特征的病毒变异的快速进化和关联表明,病毒变异在这一过程中发挥了作用。在这里,我们回顾了关于HIV-1变异和疾病的文献,并讨论了病毒适应性对传播和疾病的重要性。
{"title":"HIV-1 Transmission, Replication Fitness and Disease Progression.","authors":"Tasha Biesinger,&nbsp;Jason T Kimata","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Upon transmission, human immunodeficiency virus type 1 (HIV-1) establishes infection of the lymphatic reservoir, leading to profound depletion of the memory CD4(+) T cell population, despite the induction of the adaptive immune response. The rapid evolution and association of viral variants having distinct characteristics with different stages of infection, the level of viral burden, and rate of disease progression suggest a role for viral variants in this process. Here, we review the literature on HIV-1 variants and disease and discuss the importance of viral fitness for transmission and disease.</p>","PeriodicalId":39174,"journal":{"name":"Virology: Research and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846839/pdf/nihms79200.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28890306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Rotavirus VP6-Specific CD4+ T Cell Epitopes in a G1P[8] Human Rotavirus-Infected Rhesus Macaque. 轮状病毒vp6特异性CD4+ T细胞表位在恒河猴G1P中的鉴定[8]。
Q1 Medicine Pub Date : 2008-03-03 DOI: 10.4137/vrt.s563
Wei Zhao, Bapi Pahar, Karol Sestak

A non-human primate model was used to evaluate its potential for identification of rotavirus viral protein 6 (VP6) CD4+ T cell epitopes. Four juvenile rhesus macaques were inoculated with a mixed inoculum (G1P[8] and G9P[8]) of human rotaviruses. Infection accompanied by G1P[8] shedding was achieved in the two macaques that had no rotavirus immunoglobulin A (IgA) in plasma. To measure the interferon gamma (IFN-γ) and tumor necrosis factor (TNF) anti-viral cytokines produced by peripheral CD4+ cells that recognize VP6 epitopes, whole blood cells from one infected macaque were stimulated in vitro with VP6 peptides. Stimulation with peptide pools derived from the simian rotavirus VP6(161-395) region revealed reactivity of CD4+ T cells with the VP6(281-331) domain. A VP6(301-315) region was identified as the epitope responsible for IFN-γ production while a broader VP6(293-327) domain was linked to TNF production. These results suggest that human rotavirus-infected macaques can be used for identification of additional epitopes and domains to address specific questions related to the development of pediatric vaccines.

利用非人灵长类动物模型评价其鉴定轮状病毒病毒蛋白6 (VP6) CD4+ T细胞表位的潜力。用人类轮状病毒G1P[8]和G9P[8]混合接种剂接种4只幼年恒河猴。在血浆中没有轮状病毒免疫球蛋白A (IgA)的两只猕猴中,出现了G1P[8]脱落的感染。为了检测识别VP6表位的外周血CD4+细胞产生的干扰素γ (IFN-γ)和肿瘤坏死因子(TNF)抗病毒细胞因子,我们在体外用VP6肽刺激一只感染猕猴的全血细胞。来源于猴轮状病毒VP6(161-395)区域的肽池刺激显示CD4+ T细胞对VP6(281-331)区域具有反应性。VP6(301-315)区域被确定为负责IFN-γ产生的表位,而更广泛的VP6(293-327)区域与TNF的产生有关。这些结果表明,人类轮状病毒感染的猕猴可用于鉴定额外的表位和结构域,以解决与儿科疫苗开发相关的具体问题。
{"title":"Identification of Rotavirus VP6-Specific CD4+ T Cell Epitopes in a G1P[8] Human Rotavirus-Infected Rhesus Macaque.","authors":"Wei Zhao,&nbsp;Bapi Pahar,&nbsp;Karol Sestak","doi":"10.4137/vrt.s563","DOIUrl":"https://doi.org/10.4137/vrt.s563","url":null,"abstract":"<p><p>A non-human primate model was used to evaluate its potential for identification of rotavirus viral protein 6 (VP6) CD4+ T cell epitopes. Four juvenile rhesus macaques were inoculated with a mixed inoculum (G1P[8] and G9P[8]) of human rotaviruses. Infection accompanied by G1P[8] shedding was achieved in the two macaques that had no rotavirus immunoglobulin A (IgA) in plasma. To measure the interferon gamma (IFN-γ) and tumor necrosis factor (TNF) anti-viral cytokines produced by peripheral CD4+ cells that recognize VP6 epitopes, whole blood cells from one infected macaque were stimulated in vitro with VP6 peptides. Stimulation with peptide pools derived from the simian rotavirus VP6(161-395) region revealed reactivity of CD4+ T cells with the VP6(281-331) domain. A VP6(301-315) region was identified as the epitope responsible for IFN-γ production while a broader VP6(293-327) domain was linked to TNF production. These results suggest that human rotavirus-infected macaques can be used for identification of additional epitopes and domains to address specific questions related to the development of pediatric vaccines.</p>","PeriodicalId":39174,"journal":{"name":"Virology: Research and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/vrt.s563","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28930189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Cytomegalovirus Disease Amongst Renal Transplant Recipients in Australia and New Zealand 澳大利亚和新西兰肾移植受者的巨细胞病毒病
Q1 Medicine Pub Date : 2008-01-01 DOI: 10.4137/VRT.S920
H. Seale, D. Dwyer, J. Chapman, C. Macintyre
Cytomegalovirus (CMV) is a significant pathogen causing disease in renal transplant patients. The highest incidence of CMV disease occurs during the first 3 months post-transplant and is most problematic in CMV-naïve transplant recipients. In this study, we conducted a retrospective review of two databases, the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) and the National Hospital Morbidity Database, from the Australian Institute of Health and Welfare (AIHW), to examine CMV in renal transplant recipients. The first source looked at CMV serostatus at the time of transplantation and the second recorded hospital admissions for recipients with invasive CMV disease. From the ANZDATA registry, we obtained information from 13,530 renal transplants recipients from 1980 to 2004. Of these recipients, 7808 had a known CMV serostatus, of which 65.7% (5134/7808) had a positive sero antibody status and 34.2% (2674/7808) had a negative sero antibody status. In univariate analysis, factors significantly associated with renal rejection were being male, recipient age <50 years, being diabetic, being diagnosed with cancer at some point and having a positive EBV status. Positive CMV serostatus was not a contributing factor. Between 1993 and 2001 there were 1445 renal transplant recipients hospitalized in Australia with a diagnosis of CMV disease, of which 38% (554/1445) had CMV disease as a principal diagnoses. The average annual rate of admissions with any diagnosis was 3871 episodes per 100,000 people living with a functioning graft. Preventative strategies for CMV in renal transplant recipients should be a priority. New vaccines for CMV may soon be available and renal transplant recipients would be a suitable target group for vaccination.
巨细胞病毒(CMV)是引起肾移植患者疾病的重要病原体。巨细胞病毒疾病的最高发病率发生在移植后的前3个月,在CMV-naïve移植受者中最成问题。在这项研究中,我们对澳大利亚和新西兰透析和移植登记处(ANZDATA)和澳大利亚卫生与福利研究所(AIHW)的国家医院发病率数据库这两个数据库进行了回顾性审查,以检查肾移植受者的巨细胞病毒。第一个来源观察了移植时的巨细胞病毒血清状态,第二个来源记录了侵袭性巨细胞病毒疾病受者的住院情况。从ANZDATA注册表中,我们获得了1980年至2004年间13530名肾移植受者的信息。在这些接受者中,7808人有已知的CMV血清状态,其中65.7%(5134/7808)有血清抗体阳性状态,34.2%(2674/7808)有血清抗体阴性状态。在单因素分析中,与肾排斥反应显著相关的因素是男性、受体年龄<50岁、患有糖尿病、在某些时候被诊断患有癌症以及EBV阳性。巨细胞病毒阳性血清状态不是影响因素。1993年至2001年间,澳大利亚有1445名肾移植受者因巨细胞病毒疾病住院,其中38%(554/1445)的主要诊断为巨细胞病毒疾病。任何诊断的年平均入院率为每10万人中有3871例移植物功能正常。肾移植受者巨细胞病毒的预防策略应该是优先考虑的。针对巨细胞病毒的新疫苗可能很快就会出现,肾移植受者将是接种疫苗的合适目标群体。
{"title":"Cytomegalovirus Disease Amongst Renal Transplant Recipients in Australia and New Zealand","authors":"H. Seale, D. Dwyer, J. Chapman, C. Macintyre","doi":"10.4137/VRT.S920","DOIUrl":"https://doi.org/10.4137/VRT.S920","url":null,"abstract":"Cytomegalovirus (CMV) is a significant pathogen causing disease in renal transplant patients. The highest incidence of CMV disease occurs during the first 3 months post-transplant and is most problematic in CMV-naïve transplant recipients. In this study, we conducted a retrospective review of two databases, the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) and the National Hospital Morbidity Database, from the Australian Institute of Health and Welfare (AIHW), to examine CMV in renal transplant recipients. The first source looked at CMV serostatus at the time of transplantation and the second recorded hospital admissions for recipients with invasive CMV disease. From the ANZDATA registry, we obtained information from 13,530 renal transplants recipients from 1980 to 2004. Of these recipients, 7808 had a known CMV serostatus, of which 65.7% (5134/7808) had a positive sero antibody status and 34.2% (2674/7808) had a negative sero antibody status. In univariate analysis, factors significantly associated with renal rejection were being male, recipient age <50 years, being diabetic, being diagnosed with cancer at some point and having a positive EBV status. Positive CMV serostatus was not a contributing factor. Between 1993 and 2001 there were 1445 renal transplant recipients hospitalized in Australia with a diagnosis of CMV disease, of which 38% (554/1445) had CMV disease as a principal diagnoses. The average annual rate of admissions with any diagnosis was 3871 episodes per 100,000 people living with a functioning graft. Preventative strategies for CMV in renal transplant recipients should be a priority. New vaccines for CMV may soon be available and renal transplant recipients would be a suitable target group for vaccination.","PeriodicalId":39174,"journal":{"name":"Virology: Research and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/VRT.S920","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70717506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
HIV-1 Transmission, Replication Fitness and Disease Progression HIV-1的传播、复制适应性和疾病进展
Q1 Medicine Pub Date : 2008-01-01 DOI: 10.4137/VRT.S860
Tasha Biesinger, J. Kimata
Upon transmission, human immunodeficiency virus type 1 (HIV-1) establishes infection of the lymphatic reservoir, leading to profound depletion of the memory CD4+ T cell population despite the induction of the adaptive immune response. The rapid evolution and association of viral variants having distinct characteristics during different stages of infection, the level of viral burden, and rate of disease progression suggest a role for viral variants in this process. Here, we review the literature on HIV-1 variants and disease and discuss the importance of viral fitness for transmission and disease.
在传播后,人类免疫缺陷病毒1型(HIV-1)建立淋巴库感染,导致记忆性CD4+ T细胞群的严重耗竭,尽管诱导了适应性免疫反应。在感染的不同阶段、病毒负担水平和疾病进展速度中具有不同特征的病毒变异的快速进化和关联表明,病毒变异在这一过程中发挥了作用。在这里,我们回顾了关于HIV-1变异和疾病的文献,并讨论了病毒适应性对传播和疾病的重要性。
{"title":"HIV-1 Transmission, Replication Fitness and Disease Progression","authors":"Tasha Biesinger, J. Kimata","doi":"10.4137/VRT.S860","DOIUrl":"https://doi.org/10.4137/VRT.S860","url":null,"abstract":"Upon transmission, human immunodeficiency virus type 1 (HIV-1) establishes infection of the lymphatic reservoir, leading to profound depletion of the memory CD4+ T cell population despite the induction of the adaptive immune response. The rapid evolution and association of viral variants having distinct characteristics during different stages of infection, the level of viral burden, and rate of disease progression suggest a role for viral variants in this process. Here, we review the literature on HIV-1 variants and disease and discuss the importance of viral fitness for transmission and disease.","PeriodicalId":39174,"journal":{"name":"Virology: Research and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/VRT.S860","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70717363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
期刊
Virology: Research and Treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1